Soleno Therapeutics (SLNO) Other Accumulated Expenses (2018 - 2026)

Soleno Therapeutics (SLNO) has 9 years of Other Accumulated Expenses data on file, last reported at $24.9 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 697.28% year-over-year to $24.9 million in Q1 2026; TTM through Mar 2026 was $24.9 million, a 697.28% increase from a year earlier, with the FY2025 full-year figure at $18.2 million, up 298.82% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $24.9 million, up from $18.2 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for SLNO reached as high as $24.9 million in Q1 2026 and fell as low as $415000.0 in Q2 2022.
• Historically, Other Accumulated Expenses has averaged $5.0 million across 5 years, with a median of $1.5 million in 2024.
• Across the five-year window, Other Accumulated Expenses grew 23.61% in 2023 and surged 697.28% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $484000.0 in 2022, then surged by 221.28% to $1.6 million in 2023, then soared by 193.44% to $4.6 million in 2024, then soared by 298.82% to $18.2 million in 2025, then jumped by 37.0% to $24.9 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $24.9 million in Q1 2026, $18.2 million in Q4 2025, and $17.2 million in Q3 2025.